Connect Biopharma Holdings Ltd
Connect Biopharma is a clinical-stage company developing rademikibart, an antibody targeting IL-4Rα for acute exacerbations of asthma and COPD.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
Connect Biopharma is a clinical-stage company developing rademikibart, an antibody targeting IL-4Rα for acute exacerbations of asthma and COPD.
November 2026
September 2026
August 2026